Medincell to Participate in Jefferies and Evercore Investor Conferences in the U.S. in June

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced that Christophe Douat, Chief Executive Officer, and Grace Kim, Chief Strategy Officer, U.S. Finance, will participate in the following leading U.S. investor conferences: Jefferies Annual NY Biotech Conference Dates: June 2-4, 2026 Location: New-York Presentation: 9:55 AM ET Jun.